Flynn Pharma Ltd.

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Antibiotics market insights - Continue Reading Technavio has announced its latest market research report titled Global Antibiotics Market 2023-2027 Vendors: 15+, Including Abbott Laboratories, AbbVie Inc., Armata Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd, Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Flynn Pharma Ltd., GlaxoSmithKline Plc, Incepta Pharmaceuticals Ltd., Johnson and Johnson, Lupin Ltd., Mayne Pharma Group Ltd., Melinta Therapeutics LLC, Merck KGaA, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. among others Coverage: Parent market analysis; key drivers, major trends, and challenges; customer and vendor landscape; vendor product insights and recent developments; key vendors; and market positioning of vendors Segments: Product (broad-spectrum antibiotics and narrow-spectrum antibiotics), route of administration (intravenous, oral, and others), and geography (Asia, North America, Europe, and Rest of World). To understand more about the antibiotics market, request a sample report The antibiotics market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects. Why Buy? Add credibility to strategy Analyzes competitor's offerings Get a holistic view of the market Grow your profit margin with Technavio- Buy the Report In 2017, the antibiotics market was valued at USD 40,633.93 million. From a regional perspective, Asia held the largest market share, valued at USD 14,893.29 million. The antibiotics market size is estimated to grow by USD 17,066.66 million from 2022 to 2027 at a CAGR of 6.07% according to Technavio. Antibiotics market - Customer landscape To help companies evaluate and develop growth strategies, the report outlines – Key purchase criteria Adoption rates Adoption lifecycle Drivers of price sensitivity For highlights on customer landscape analysis, download a sample! Global antibiotics market - Vendor insights The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market's competitive landscape and offers information on several market vendors including - AbbVie Inc: The company offers HUMIRA antibiotics drug which is designed to reduce pain and swelling. Astellas Pharma Inc: The company offers XTANDI which is designed as a prescription medicine to treat men with prostate cancer issues. Aspen Pharmacare Holdings Ltd: The company offers Aggrastat antibiotic medicine which is designed to treat the symptoms of blood clots and heart attack issues. Global antibiotics market – Market dynamics Major drivers- Rising prevalence of infectious diseases Growing awareness of various diseases and their treatment Special regulatory designations KEY challenges – Development of antibiotic-resistant strains Entry of generics The limited interest of pharmaceutical companies in investing in antibiotic research activities Drivers, & Challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report! What are the key data covered in this antibiotics market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the antibiotics market between 2023 and 2027 Precise estimation of the size of the antibiotics market and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the antibiotics market across Asia, North America, Europe, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of antibiotics market vendors Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports: Anti-inflammatory Therapeutics Market by Application, Drug Class, and Geography - Forecast and Analysis 2023-2027: The anti-inflammatory therapeutics market is estimated to grow at a CAGR of 6.7% between 2022 and 2027. The size of the market is forecast to increase by USD 39.32 billion. The unmet need for safer biologics for RA is notably driving the market growth, although factors such as the loss of patents may impede market growth. Anti-obesity Drugs Market by Type, Drug Class, and Geography - Forecast and Analysis 2023-2027: The anti-obesity drugs market is estimated to grow at a CAGR of 12.5% between 2022 and 2027. The size of the market is forecast to increase by USD 13,693.43 million. The growing obese population is notably driving the market growth, although factors such as limited reimbursement for anti-obesity drugs may impede the market growth. Browse for Technavio "Health Care" Research Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global antibiotics market 2022 - 2027 Exhibit 18: Historic Market Size – Data Table on Global antibiotics market 2022 - 2027 ($ million) 4.2 Product Segment Analysis 2022 - 2027 Exhibit 19: Historic Market Size – Product Segment 2022 - 2027 ($ million) 4.3 Route of administration Segment Analysis 2022 - 2027 Exhibit 20: Historic Market Size – Route of administration Segment 2022 - 2027 ($ million) 4.4 Geography Segment Analysis 2022 - 2027 Exhibit 21: Historic Market Size – Geography Segment 2022 - 2027 ($ million) 4.5 Country Segment Analysis 2022 - 2027 Exhibit 22: Historic Market Size – Country Segment 2022 - 2027 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Product 6.1 Market segments Exhibit 30: Chart on Product - Market share 2022-2027 (%) Exhibit 31: Data Table on Product - Market share 2022-2027 (%) 6.2 Comparison by Product Exhibit 32: Chart on Comparison by Product Exhibit 33: Data Table on Comparison by Product 6.3 Broad-spectrum antibiotics - Market size and forecast 2022-2027 Exhibit 34: Chart on Broad-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Broad-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Broad-spectrum antibiotics - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Broad-spectrum antibiotics - Year-over-year growth 2022-2027 (%) 6.4 Narrow-spectrum antibiotics - Market size and forecast 2022-2027 Exhibit 38: Chart on Narrow-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Narrow-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Narrow-spectrum antibiotics - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Narrow-spectrum antibiotics - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Product Exhibit 42: Market opportunity by Product ($ million) 7 Market Segmentation by Route of Administration 7.1 Market segments Exhibit 43: Chart on Route of Administration - Market share 2022-2027 (%) Exhibit 44: Data Table on Route of Administration - Market share 2022-2027 (%) 7.2 Comparison by Route of Administration Exhibit 45: Chart on Comparison by Route of Administration Exhibit 46: Data Table on Comparison by Route of Administration 7.3 Intravenous - Market size and forecast 2022-2027 Exhibit 47: Chart on Intravenous - Market size and forecast 2022-2027 ($ million) Exhibit 48: Data Table on Intravenous - Market size and forecast 2022-2027 ($ million) Exhibit 49: Chart on Intravenous - Year-over-year growth 2022-2027 (%) Exhibit 50: Data Table on Intravenous - Year-over-year growth 2022-2027 (%) 7.4 Oral - Market size and forecast 2022-2027 Exhibit 51: Chart on Oral - Market size and forecast 2022-2027 ($ million) Exhibit 52: Data Table on Oral - Market size and forecast 2022-2027 ($ million) Exhibit 53: Chart on Oral - Year-over-year growth 2022-2027 (%) Exhibit 54: Data Table on Oral - Year-over-year growth 2022-2027 (%) 7.5 Others - Market size and forecast 2022-2027 Exhibit 55: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 56: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 57: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 58: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.6 Market opportunity by Route of Administration Exhibit 59: Market opportunity by Route of Administration ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 61: Chart on Market share by geography 2022-2027 (%) Exhibit 62: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 63: Chart on Geographic comparison Exhibit 64: Data Table on Geographic comparison 9.3 Asia - Market size and forecast 2022-2027 Exhibit 65: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 66: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 67: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 68: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.4 North America - Market size and forecast 2022-2027 Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.5 Europe - Market size and forecast 2022-2027 Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 China - Market size and forecast 2022-2027 Exhibit 85: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 86: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 87: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on China - Year-over-year growth 2022-2027 (%) 9.9 India - Market size and forecast 2022-2027 Exhibit 89: Chart on India - Market size and forecast 2022-2027 ($ million) Exhibit 90: Data Table on India - Market size and forecast 2022-2027 ($ million) Exhibit 91: Chart on India - Year-over-year growth 2022-2027 (%) Exhibit 92: Data Table on India - Year-over-year growth 2022-2027 (%) 9.10 UK - Market size and forecast 2022-2027 Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 101: Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 102: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 103: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 104: Overview on factors of disruption 11.4 Industry risks Exhibit 105: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 106: Vendors covered 12.2 Market positioning of vendors Exhibit 107: Matrix on vendor position and classification 12.3 Abbott Laboratories Exhibit 108: Abbott Laboratories - Overview Exhibit 109: Abbott Laboratories - Business segments Exhibit 110: Abbott Laboratories - Key news Exhibit 111: Abbott Laboratories - Key offerings Exhibit 112: Abbott Laboratories - Segment focus 12.4 AbbVie Inc. Exhibit 113: AbbVie Inc. - Overview Exhibit 114: AbbVie Inc. - Product / Service Exhibit 115: AbbVie Inc. - Key news Exhibit 116: AbbVie Inc. - Key offerings 12.5 Aspen Pharmacare Holdings Ltd Exhibit 117: Aspen Pharmacare Holdings Ltd - Overview Exhibit 118: Aspen Pharmacare Holdings Ltd - Business segments Exhibit 119: Aspen Pharmacare Holdings Ltd - Key offerings Exhibit 120: Aspen Pharmacare Holdings Ltd - Segment focus 12.6 Astellas Pharma Inc. Exhibit 121: Astellas Pharma Inc. - Overview Exhibit 122: Astellas Pharma Inc. - Product / Service Exhibit 123: Astellas Pharma Inc. - Key offerings 12.7 Aurobindo Pharma Ltd. Exhibit 124: Aurobindo Pharma Ltd. - Overview Exhibit 125: Aurobindo Pharma Ltd. - Product / Service Exhibit 126: Aurobindo Pharma Ltd. - Key offerings 12.8 Bayer AG Exhibit 127: Bayer AG - Overview Exhibit 128: Bayer AG - Business segments Exhibit 129: Bayer AG - Key offerings Exhibit 130: Bayer AG - Segment focus 12.9 F. Hoffmann La Roche Ltd. Exhibit 131: F. Hoffmann La Roche Ltd. - Overview Exhibit 132: F. Hoffmann La Roche Ltd. - Business segments Exhibit 133: F. Hoffmann La Roche Ltd. - Key news Exhibit 134: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 135: F. Hoffmann La Roche Ltd. - Segment focus 12.10 GlaxoSmithKline Plc Exhibit 136: GlaxoSmithKline Plc - Overview Exhibit 137: GlaxoSmithKline Plc - Business segments Exhibit 138: GlaxoSmithKline Plc - Key offerings Exhibit 139: GlaxoSmithKline Plc - Segment focus 12.11 Incepta Pharmaceuticals Ltd. Exhibit 140: Incepta Pharmaceuticals Ltd. - Overview Exhibit 141: Incepta Pharmaceuticals Ltd. - Product / Service Exhibit 142: Incepta Pharmaceuticals Ltd. - Key offerings 12.12 Johnson and Johnson Exhibit 143: Johnson and Johnson - Overview Exhibit 144: Johnson and Johnson - Business segments Exhibit 145: Johnson and Johnson - Key news Exhibit 146: Johnson and Johnson - Key offerings Exhibit 147: Johnson and Johnson - Segment focus 12.13 Lupin Ltd. Exhibit 148: Lupin Ltd. - Overview Exhibit 149: Lupin Ltd. - Product / Service Exhibit 150: Lupin Ltd. - Key news Exhibit 151: Lupin Ltd. - Key offerings 12.14 Mayne Pharma Group Ltd. Exhibit 152: Mayne Pharma Group Ltd. - Overview Exhibit 153: Mayne Pharma Group Ltd. - Business segments Exhibit 154: Mayne Pharma Group Ltd. - Key offerings Exhibit 155: Mayne Pharma Group Ltd. - Segment focus 12.15 Merck KGaA Exhibit 156: Merck KGaA - Overview Exhibit 157: Merck KGaA - Business segments Exhibit 158: Merck KGaA - Key news Exhibit 159: Merck KGaA - Key offerings Exhibit 160: Merck KGaA - Segment focus 12.16 Pfizer Inc. Exhibit 161: Pfizer Inc. - Overview Exhibit 162: Pfizer Inc. - Product / Service Exhibit 163: Pfizer Inc. - Key news Exhibit 164: Pfizer Inc. - Key offerings 12.17 Sanofi SA Exhibit 165: Sanofi SA - Overview Exhibit 166: Sanofi SA - Business segments Exhibit 167: Sanofi SA - Key news Exhibit 168: Sanofi SA - Key offerings Exhibit 169: Sanofi SA - Segment focus 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 170: Inclusions checklist Exhibit 171: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 172: Currency conversion rates for US$ 13.4 Research methodology Exhibit 173: Research methodology Exhibit 174: Validation techniques employed for market sizing Exhibit 175: Information sources 13.5 List of abbreviations Exhibit 176: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Pfizer and Flynn Pharma are under the scrutiny of British watchdogs once again, after officials said the companies have been overcharging for an anti-epilepsy medication for over four years. A fine totaling $84 million, or 70 million pounds, has been issued to the two companies. This marks the second time that the Competition and Markets Authority (CMA) has issued a negative finding, coupled with a fine, to Pfizer and Flynn for the alleged infraction. The CMA serves as a U.K. regulatory body tasked with regulating the consumer market to ensure fair treatment of consumers. In that role, the regulator protects the National Health Services (NHS), the country’s public health system. According to a 2021 statement by CMA officials regarding suspicions of overcharging, the country was left with little option but to pay the high price. “As Pfizer and Flynn were the dominant suppliers of the drug in the U.K., the NHS had no choice but to pay unfairly high prices for this vital medicine,” the agency said. The CMA’s decision this week has a roller coaster of a background. The drug was sold under the brand name Epanutin by Pfizer without reports of price gouging. In 2012, the anti-epilepsy drug was de-branded. Without a brand name, the drug evaded strict regulatory rules that accompany branding, the regulator said. Pfizer then allegedly began distribution through Flynn at a price exceeding 2,000% of the brand-name cost. The CMA fired back and accused Pfizer of taking advantage of the loophole to be able to manipulate pricing without regulation. A report issued by the CMA noted that the NHS spent roughly 25 times more in 2013 than it had in 2012 to ensure that U.K. patients were able to receive the life-saving drug. In 2016, the CMA issued a fine of roughly $107 million, or 90 million pounds, accusing the companies of inflating the price of the drug by approximately 2,600% to 67.50 pounds for a 100mg pack. In 2018, Pfizer and Flynn appealed the decision, with success. The pair is expected to attempt an appeal this time around as well, telling Reuters they are “Surprised and disappointed at the Competition and Markets Authority (CMA) issuance of a further (second) Decision finding an abuse of competition law on the part of Flynn.” A similar issue made U.S. headlines right around the same time as the CMA’s 2016 decision. Pfizer’s Meridian Medical, subcontracted by Mylan, was producing EpiPens when the pair were accused of overcharging for the life-saving epinephrine injector. Early into its lifespan, the EpiPens cost was about $57 each. In 2016, two pens could be purchased at an increased price of $600. Following an accusation by the U.S. Justice Department that the EpiPen was misclassified as a generic product, thereby skirting regulations, Mylan paid a $465 million settlement.

When a drugmaker raises the price of a drug in the US by more than 2,000% overnight, and without any particular reason for that increase, nothing typically happens to the company. No fines, no court orders, just business as usual. Martin Shkreli’s decades-old anti-parasitic drug Daraprim was the perfect example — massive price spike on an old drug, lots of media attention, public outcry, congressional committees dragging his former company through multiple hearings, and at the end of it? Nothing happened to the price or the company (until generic competition came). But when this type of behavior occurs in the UK, as we’re now seeing in this case with Pfizer, regulators are prepared for retribution, and they aren’t afraid to re-open an investigation either. In this instance, the UK’s Competition and Markets Authority has already, in 2016, imposed a record £84.2 million ($117 million) fine on Pfizer, finding that the company broke competition law by increasing the price of its epilepsy drug phenytoin sodium by 2,600% overnight after the drug was deliberately de-branded in September 2012. The change meant that the price the UK’s National Health Service was charged for 100mg packs of the drug skyrocketed from £2.83 ($3.94) to £67.50 ($94), resulting in increased expenditures from about £2 million ($2.8 million) in 2012 to about £50 million ($70 million) in 2013. In 2018, the UK’s Competition Appeal Tribunal (CAT) upheld the CMA’s findings on market definition and dominance, but set aside the CMA’s finding that the companies’ prices were an unlawful “abuse” of dominance. This latest re-investigation by the CMA, announced Thursday, will wade back into that finding that the CAT set aside. The CMA has now provisionally found that Pfizer and Flynn Pharma, the company that sold the Pfizer drug to NHS and previously was fined £5.2 million ($7.2 million), exploited a loophole and de-branded the drug – known as Epanutin prior to September 2012 – so that it was not subject to price regulation in the way branded drugs are. As Pfizer and Flynn were the dominant suppliers of phenytoin sodium in the UK, the NHS had no choice but to pay the high prices. Pfizer and Flynn now have a chance to respond to the CMA’s accusations, and the authority said it will carefully consider their representations before deciding whether they broke the law.